The Medicinal Metallochemistry of Alzheimers Disease

Author(s): Robert A. Cherny, Colin L. Masters, Ashley I. Bush.

Journal Name: Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents

Volume 3 , Issue 1 , 2003

Become EABM
Become Reviewer

Abstract:

The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimers amyloid protein (Aβ) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are zinc-dependent. These properties are exaggerated by conditions present in the aging brain. Amyloid from human brain specimens can be solubilized by the application of selected Cu / Zn chelators thus demonstrating the role of metals in amyloid architecture. Similarly, the toxicity of the metal / Aβ complex is ameliorated by metal complexing agents. Clioquinol, a bioavailable Cu / Zn chelator has been successfully used to inhibit amyloid deposition in a transgenic animal model for Alzheimers disease and is presently undergoing human efficacy trials.

Keywords: metallochemistry, alzheimer disease, clioquinol

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 3
ISSUE: 1
Year: 2003
Page: [9 - 13]
Pages: 5
DOI: 10.2174/1568013033358626

Article Metrics

PDF: 6